Stock Chart
GERN
Type: SELL growth_1yr
Strike: $2
Premium: $0.55
Expiry: Jan 15, 2027
Target: $1
Score: -100
LEAPs are long-term options (1+ year) with less time decay.
Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech
Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity
Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
About GERN - Geron Corp
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products …
Key Statistics
More GERN Analysis
This GERN stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track GERN's price movements with trendlines, gamma walls, and key support/resistance levels.